Adicet Bio (NASDAQ:ACET) Now Covered by Analysts at Jefferies Financial Group

Equities research analysts at Jefferies Financial Group began coverage on shares of Adicet Bio (NASDAQ:ACET) in a report issued on Tuesday. The brokerage set a “buy” rating and a $19.00 price target on the stock. Jefferies Financial Group’s price objective indicates a potential upside of 124.85% from the company’s previous close.

Other analysts have also recently issued reports about the company. HC Wainwright dropped their price target on Adicet Bio from $50.00 to $27.00 and set a “buy” rating for the company in a research report on Monday, March 23rd. Weiss Ratings upgraded Adicet Bio from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, April 24th. Canaccord Genuity Group set a $18.00 target price on shares of Adicet Bio and gave the stock a “buy” rating in a report on Tuesday, January 6th. Wall Street Zen upgraded shares of Adicet Bio from a “strong sell” rating to a “sell” rating in a research report on Saturday. Finally, Truist Financial upgraded shares of Adicet Bio to a “strong-buy” rating in a research report on Wednesday, March 25th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Adicet Bio has a consensus rating of “Moderate Buy” and an average target price of $48.80.

Adicet Bio Stock Up 3.0%

Adicet Bio stock opened at $8.45 on Tuesday. The business’s 50-day moving average price is $7.24 and its 200 day moving average price is $8.62. The firm has a market cap of $81.09 million, a price-to-earnings ratio of -0.47 and a beta of 1.50. Adicet Bio has a 52 week low of $6.01 and a 52 week high of $17.44.

Adicet Bio (NASDAQ:ACET) last issued its quarterly earnings data on Thursday, March 12th. The company reported ($2.94) EPS for the quarter, topping analysts’ consensus estimates of ($3.23) by $0.29. Equities analysts expect that Adicet Bio will post -10.26 EPS for the current year.

Insider Buying and Selling

In related news, major shareholder Ra Capital Management, L.P. bought 74,751 shares of the company’s stock in a transaction dated Friday, February 20th. The shares were acquired at an average price of $7.27 per share, with a total value of $543,439.77. Following the completion of the acquisition, the insider owned 1,182,624 shares in the company, valued at approximately $8,597,676.48. This trade represents a 6.75% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have acquired 223,596 shares of company stock valued at $1,603,934 in the last quarter. Insiders own 4.60% of the company’s stock.

Institutional Trading of Adicet Bio

Several hedge funds and other institutional investors have recently made changes to their positions in ACET. Susquehanna International Group LLP purchased a new position in Adicet Bio in the third quarter valued at about $33,000. Squarepoint Ops LLC purchased a new stake in shares of Adicet Bio during the 3rd quarter worth approximately $38,000. FNY Investment Advisers LLC purchased a new stake in shares of Adicet Bio during the 4th quarter worth approximately $51,000. Virtu Financial LLC acquired a new stake in shares of Adicet Bio in the 3rd quarter worth approximately $65,000. Finally, Maven Securities LTD acquired a new stake in shares of Adicet Bio in the 4th quarter worth approximately $263,000. Institutional investors and hedge funds own 83.89% of the company’s stock.

About Adicet Bio

Adicet Bio, Inc (NASDAQ: ACET) is a clinical‐stage biotechnology company specializing in the development of off‐the‐shelf, allogeneic gamma delta (γδ) T cell therapies for oncology and autoimmune disorders. The company’s proprietary platform enables the genetic engineering of γδ T cells with chimeric antigen receptors (CARs) and other molecular modifications to enhance tumor targeting, expansion, and persistence. By leveraging the innate tumor-recognition properties of γδ T cells, Adicet seeks to overcome the manufacturing and safety challenges associated with autologous cell therapies.

Adicet’s lead product candidate, ADI-001, is a CAR‐engineered allogeneic γδ T cell therapy directed against CD20 for the treatment of relapsed or refractory B-cell malignancies.